1 – 5 of 5
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months
(
- Contribution to journal › Article
- 2016
-
Mark
Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.
2016) In Journal of the Pediatric Infectious Diseases Society(
- Contribution to journal › Article
- 2006
-
Mark
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
(
- Contribution to journal › Article
- 2004
-
Mark
A population-based study of cervical carcinoma and HPV infection in Latvia.
(
- Contribution to journal › Article
- 2002
-
Mark
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients.
(
- Contribution to journal › Article